INTC vs MRK: Which Is the Better Buy?
Side-by-side comparison of Intel Corporation and Merck & Co., Inc. — fair value, conviction, valuation metrics, and QuantHub research signals.
Updated 2026-04-16.
Intel Corporation · Technology
$68.50
-13.9% upside to fair value
High Conviction
Grade D
VS
Merck & Co., Inc. · Healthcare
$121.42
-2.9% upside to fair value
Med Conviction
Grade B
QuantHub Verdict
MRK has more upside to fair value
(-2.9%).
These are model outputs — not personalized investment advice.
See all research →
Valuation & Fundamentals
| Metric |
INTC |
MRK |
| Current Price |
$68.50 |
$121.42 |
| Fair Value Estimate |
$59.00 |
$118.00 |
| Upside to Fair Value |
-13.9%
|
-2.9%
|
| Market Cap |
$343.9B |
$300.2B |
| Forward P/E |
-1245.8x
|
14.0x
|
| EV / EBITDA |
—
|
11.8x
|
| Price / Sales |
6.5x
|
4.1x
|
| Price / FCF |
-69.5x
|
21.4x
|
| Revenue Growth YoY |
+0.2%
|
+1.3%
|
| Gross Margin |
34.8%
|
81.5%
|
| Operating Margin |
-4.2%
|
41.2%
|
| Return on Equity |
-0.3%
|
34.7%
|
| Dividend Yield |
— |
3.1% |
| FCF Yield |
—
|
4.7%
|
| Analyst Consensus |
Hold
|
Buy
|
Investment Thesis
Intel is a legacy semiconductor leader attempting an ambitious turnaround under new CEO Lip-Bu Tan, pivoting from a pure-play chipmaker to an integrated device manufacturer (IDM 2.0) with foundry ambitions. The business remains structurally challenged: PC market share is eroding, foundry execution is unproven, negative free cash flow persists, and margins are compressed. However, the stock trades…
Merck is a top-5 global pharmaceutical company generating $65B in annual revenue with 81.5% gross margins and 28% net margins. Keytruda, the world's best-selling drug at $31.7B (49% of pharma revenue), faces patent expiry in 2028. Merck is aggressively building replacements through M&A and pipeline launches: Winrevair ($1.4B year one), Capvaxive ($759M), and the $6.7B Terns acquisition for TERN-7…
Accumulation Zones
| Metric |
INTC |
MRK |
| Zone Low |
$44.00 |
$88.00 |
| Zone High |
$50.00 |
$100.00 |
| In Buy Zone? |
No
|
No
|